Delay in passing the FY24 budget is “disastrous for our cancer centers”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

As NCI continues to hobble along on a flat budget provided by a succession of continuing resolutions, the prospects for robust funding for cancer research, rising paylines, and healthy cancer center support grants have dimmed for this fiscal year. “The extended delay in passing the FY2024 budget is disastrous for our cancer centers,” Jennifer W....

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Alexandria Carolan
Alexandria Carolan
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

The California Institute for Regenerative Medicine, a state agency tasked with awarding billions of dollars of scientific funding for stem cell and gene therapy, has rescinded a controversial policy that was disrupting the flow of funding to cancer research.
Leadership is changing at The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute in the months to come—but the leaders of the two institutions say that this will have little if any effect on the clinical-research collaboration that they have spent the past 15years building (The Cancer Letter, July 12, 2019). 
Alexandria Carolan
Alexandria Carolan
Reporter

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login